 | |
| Clinical data | |
|---|---|
| Other names | MLD-41;N1-Methyl-Lysergic Acid Diethylamide; 1-Methyl-LSD; 1-Methyl-N,N-Diethyllysergamide; Methyl-LSD |
| Routes of administration | Oral[1][2] |
| Drug class | Serotonergic psychedelic;Hallucinogen |
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| ChemSpider |
|
| CompTox Dashboard(EPA) | |
| Chemical and physical data | |
| Formula | C21H27N3O |
| Molar mass | 337.467 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| (verify) | |
MLD-41, also known as1-methyl-LSD, is apsychedelic drug of thelysergamide family related tolysergic acid diethylamide (LSD).[1][2] It has about 33% of thepsychoactivepotency of LSD.[1][2] It has been studied with regard tocross-tolerance with LSD.[3] Extensivemetabolism of other 1-methylated lysergamides to theirsecondary aminederivatives, for instancemethysergide (1-methylmethylergometrine) conversion intomethylergometrine, has been observed.[4][5]
Metabolites of methysergide also exhibit pharmacological activity. Methylergometrine (one of methysergide's metabolites) is responsible for methysergide's therapeutic effects regarding migraine treatment (Müller-Schweinitzer and Tapparelli 1986). [...] The systemic availability of methysergide after oral administration is only 13%, due to a high degree of first-pass metabolism by N-1 demethylation to methylergometrine. After oral administration, the plasma concentrations of the metabolite are considerably higher than those of the parent drug, and the area under the plasma concentration curve (AUC) for methylergometrine is more than ten times greater than for methysergide.
 | Thishallucinogen-related article is astub. You can help Wikipedia byexpanding it. |
